Phase I – Obesity

Past Clinical Trials

Phase I – Obesity

A Phase I study was conducted in 2001 (METAOD001). LAT8881 was administered intravenously to 14 healthy male volunteers.

LAT8881 was well tolerated over the dose range. There were no clinically significant adverse events (AEs); or significant abnormalities in vital signs, safety laboratory tests or electrocardiograms (ECGs) during the study.

Drug-Dev-Program